<DOC>
	<DOC>NCT03053102</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of ACH-0144471 in currently untreated patients with PNH.</brief_summary>
	<brief_title>A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Male and female patients age 18 years or older Currently untreated PNH patients with PNH Type III erythrocyte and/or granulocyte clone size ≥ 10% and anemia (Hgb &lt; 12g/dL) with adequate reticulocytosis (as determined by the investigator) Lactate dehydrogenase (LDH) ≥ 1.5X the upper limit of normal (ULN) Platelets ≥ 50,000/uL without the need for platelet transfusions Documentation of vaccination for N. meningitidis (quadrivalent ACWY and serogroup B), H. influenza, and S. pneumoniae, or willingness to receive vaccinations during the screening period Negative pregnancy test for females prior to dosing and throughout the study History of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant Patients who have received another investigational agent within 30 days or 5 halflives of the investigational agent prior to study entry, whichever is greater Patients who have received eculizumab at any dose or interval within the past 75 days before study entry Patients with known or suspected complement deficiency Patients with active bacterial infection or clinically significant active viral infection, a body temperature &gt; 38°C, or other evidence of infection on Day 1, or with a history of febrile illness within 14 days prior to first study drug administration History of meningococcal infection, or a firstdegree relative or household contact with a history of meningococcal infection Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or patients with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PNH</keyword>
	<keyword>Paroxysmal</keyword>
	<keyword>Hemoglobinuria</keyword>
</DOC>